Fubotv earnings beat by $0.10, revenue topped estimates
Investing.com -- Daxor Corporation (NASDAQ:DXR) stock surged 40% after the company received FDA 510(k) clearance for its next-generation blood volume analysis system, a rapid, compact, hand-held device that promises to revolutionize fluid management in clinical settings.
The newly cleared Daxor BVA™ device quantifies a patient’s blood volume against patient-specific norms, providing critical data for precise fluid management across numerous medical conditions. The system processes results three times faster than its predecessor while maintaining laboratory-grade diagnostic precision in a lightweight 7-pound package that can be easily moved between clinical settings.
Volume derangement affects millions of patients annually, including those with heart failure, critical care needs, sepsis, dialysis requirements, and traumatic injuries. The economic burden of these conditions is substantial, with heart failure alone accounting for over seven million patients and one million hospitalizations each year.
Peer-reviewed studies have demonstrated significant clinical benefits from blood volume analysis guided care, including an 86% reduction in one-year mortality for heart failure patients, shorter hospital stays, 56% fewer readmissions, and lower healthcare costs. In intensive care settings, BVA-guided care was associated with a 66% reduction in mortality among predominantly septic patients.
The new analyzer builds upon Daxor’s previous BVA-100™ system, which has been used in over 75,000 tests. The company developed the new system under contract with the U.S. Department of Defense, specifically the U.S. Army and the Defense Health Agency.
Daxor’s technology aims to eliminate the inaccuracies inherent in traditional clinical assessments of fluid status, particularly in patients with complex conditions, by using tracer dilution technique, considered the gold standard for blood volume measurement.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.